{
    "nct_id": "NCT03410875",
    "official_title": "A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia",
    "inclusion_criteria": "* Patients must be >/= 18 years of age\n* Histologically confirmed classical HCL by the enrolling institution\n* Has not received any prior therapy for the disease\n* Patients who meet the standard treatment initiation criteria, as defined by ANC </=1.0, Hgb </=10.0 or PLT </=100K\n* ECOG performance status of 0-2\n* Acceptable pre-study organ function during screening as defined as:\n\n  * Total bilirubin </= 1.5 times the upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </=2.5x ULN\n  * Serum creatinine </=1.5x ULN\n* Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QT Bazett's formula) of <480 msec\n* For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib\n* For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib\n* Negative serum pregnancy test with 7 days of commencement of treatment in women of childbearing potential\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have had previous treatment for HCL, including purine analogs, rituximab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.\n* Known hypersensitivity to any of the study drugs\n* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.\n* Patients with uncorrectable electrolyte abnormalities with potassium (K) >ULN (upper limit of normal).\n* Patients with any active and uncontrolled infections (such as bacterial, fungal, and new or reactivated viral infections)\n* Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody.\n\n  * Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.\n  * Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.\n* Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)\n* Invasive malignancy that require active systemic chemotherapy or biologics that may cause significant drug-drug interaction with either vemurafenib or obinutuzumab\n* Malabsorption syndrome or other condition that precludes enteral route of administration\n* Patients with HCL variant (as defined by absence of expression of CD25)\n* Pregnant or lactating, or intending to become pregnant during the study",
    "miscellaneous_criteria": ""
}